Affiliation:
1. 1Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Abstract
Abstract
The ongoing therapeutic revolution in multiple myeloma care can be traced to the turn of the millennium with the unanticipated discovery in 1999 that the cereblon binding small molecule thalidomide had profound clinical effectiveness and, simultaneously, the emergence of a new class of targeted therapies inhibiting the proteasome, both of which ultimately target ubiquitinated protein degradation. These contemporaneous discoveries forever changed the landscape of multiple myeloma care, substantially extending survival. Foreshadowing this seismic change, Nobel Prize winning work on the proteasome ubiquitin pathway had stimulated the development of highly specific proteasome inhibitor small molecules, particularly PS-341 (later named bortezomib). An abundance of the proteasome in hematologic malignancies had been recognized and thus PS-341 was logically being explored in relevant preclinical models. Concurrent with phase I trials, which were soon to prove the significant clinical relevance of preclinical models, the laboratory of Dr. Kenneth Anderson and colleagues at Dana-Farber, in partnership with Dr. Julian Adams and scientists at ProScript (later Millennium Pharmaceuticals) first demonstrated that the proteasome inhibitor PS-341 inhibited growth, induced apoptosis, and overcame drug resistance in human multiple myeloma cells. This landmark paper in Cancer Research set the stage for a paradigm shift in how multiple myeloma was managed across all stages of the disease, which changed the lives of patients worldwide.
See related article by Hideshima and colleagues, Cancer Res 2001;61:3071–6
Publisher
American Association for Cancer Research (AACR)
Reference10 articles.
1. Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance;Wada;J Lab Clin Med,1993
2. Proteasome inhibitors: a novel class of potent and effective antitumor agents;Adams;Cancer Res,1999
3. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells;Hideshima;Cancer Res,2001
4. Proteasome inhibitor drugs;Fricker;Annu Rev Pharmacol Toxicol,2020
5. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression;Read;Immunity,1995